Physician profile
Kevin Small
NPI 1043470834
$3,346.07
in general payments reported to CMS, 2019-2025
13 companies · $29.40 in 2025
The $29.40 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $44.82 · 2021: $643 · 2022: $687 · 2023: $1,281 · 2024: $179 · 2025: $29.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,395.25 | 2019-2025 | Xeomin |
| Sientra, INC. | $644.63 | 2019-2022 | |
| Medtronic, INC. | $493.22 | 2021-2024 | Signia |
| Allergan, INC. | $261.07 | 2019 | |
| Davol INC. | $213.08 | 2021-2022 | |
| Intuitive Surgical, INC. | $95.66 | 2021 | |
| W. L. Gore & Associates, INC. | $86.09 | 2021 | |
| Covidien LP | $44.82 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $34.48 | 2019 | |
| Currax Pharmaceuticals LLC | $28.24 | 2021 | |
| Redhill Biopharma INC. | $20.35 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $15.80 | 2024 | |
| Acelrx Pharmaceuticals, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.